Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Beta variant of concern (VOC) resists neutralization by major classes of antibodies from COVID-19 patients and vaccinated individuals. In this study, serum of Beta-infected patients revealed reduced cross-neutralization of wild-type virus. From these patients, we isolated Beta-specific and cross-reactive receptor-binding domain (RBD) antibodies. The Beta-specificity results from recruitment of VOC-specific clonotypes and accommodation of mutations present in Beta and Omicron into a major antibody class that is normally sensitive to these mutations. The Beta-elicited cross-reactive antibodies share genetic and structural features with wild type–elicited antibodies, including a public VH1-58 clonotype that targets the RBD ridge. These findings advance our understanding of the antibody response to SARS-CoV-2 shaped by antigenic drift, with implications for design of next-generation vaccines and therapeutics.
Autoantibodies targeting the GABA(A) receptor (GABA(A)R) hallmark an autoimmune encephalitis presenting with frequent seizures and psychomotor abnormalities. Their pathogenic role is still not well-defined, given the common overlap with further autoantibodies and the lack of patient-derived mAbs. Five GABA(A)R mAbs from cerebrospinal fluid cells bound to various epitopes involving the alpha 1 and gamma 2 receptor subunits, with variable binding strength and partial competition. mAbs selectively reduced GABAergic currents in neuronal cultures without causing receptor internalization. Cerebroventricular infusion of GABA(A)R mAbs and Fab fragments into rodents induced a severe phenotype with seizures and increased mortality, reminiscent of encephalitis patients' symptoms. Our results demonstrate direct pathogenicity of autoantibodies on GABA(A)Rs independent of Fc-mediated effector functions and provide an animal model for GABA(A)R encephalitis. They further provide the scientific rationale for clinical treatments using antibody depletion and can serve as tools for the development of antibody-selective immunotherapies.
1 July 2026 in Neurology Neuroimmunology & Neuroinflammation
Antineuronal autoantibodies targeting surface membrane proteins are the hallmark of an increasing number of autoimmune encephalitides. The autoantibodies can be directly pathogenic and cause various symptoms ranging from epilepsy and psychosis to amnesia and autonomic dysfunction. It is largely unclear how the humoral autoimmune response is triggered and propagated. We analyzed whether affinity maturation leads to increasing affinity of encephalitis-related autoantibodies to their receptors by determining the binding strength of patient-derived monoclonal autoantibodies and their germline ancestors from 11 patients with NMDAR, LGI1, mGluR5, CASPR2, and GABAAR encephalitis. In addition, binding to foreign and self-antigens was assessed. For most autoantibodies, affinity maturation generated or increased binding to neuronal surface antigens. However, high numbers of somatic hypermutations were not necessarily needed, as half of germline-encoded variants already recognized the respective antigen with strong binders in all groups. 10%–15% of reverted and mutated monoclonal autoantibodies recognized nuclear antigens, and one-third were reactive to mammalian tissues other than brain. Immunoprecipitation combined with mass spectrometry identified the nuclear antigen proteins major vault protein and translocated promotor region as targets of selected germline ancestors. The findings suggest analogous immunologic mechanisms across 5 different encephalitides, with high-affinity autoantibodies already in the germline pool and frequent reactivity to nuclear antigens. Future studies should determine the contribution of immunologic checkpoint deficiencies, as seen in one patient with a pathogenic immune checkpoint mutation.
Implantation of left ventricular assist devices (LVADs) is increasingly utilized, prolonging survival of patients with advanced heart failure. We herein report a severe complication of gastric perforation with an intragastric transposition of an LVAD driveline (DL). The patient was admitted to interdisciplinary surgery, where the DL was successfully removed from the stomach and the gastric perforation addressed by performing an atypical gastric resection. This is the first reported case of an intragastric transposition of DL and LVAD pump of a HeartMate II LVAD. This case underscores the importance of interdisciplinary efforts in the treatment of LVAD associated complications as well as regular gastrointestinal monitoring in LVAD patients.